Earnings Update: Here's Why Analysts Just Lifted Their Indegene Limited (NSE:INDGN) Price Target To ₹660
Investors in Indegene Limited (NSE:INDGN) had a good week, as its shares rose 2.6% to close at ₹587 following the release of its quarterly results. It was a credible result overall, with revenues of ₹11b and statutory earnings per share of ₹4.64 both in line with analyst estimates, showing that Indegene is executing in line with expectations. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
Taking into account the latest results, the current consensus from Indegene's six analysts is for revenues of ₹45.7b in 2027. This would reflect a decent 11% increase on its revenue over the past 12 months. Per-share earnings are expected to leap 27% to ₹21.61. Yet prior to the latest earnings, the analysts had been anticipated revenues of ₹44.7b and earnings per share (EPS) of ₹21.96 in 2027. So it looks like there's been no major change in sentiment following the latest results, although the analysts have made a small increase to to revenue forecasts.
Check out our latest analysis for Indegene
The consensus price target increased 6.3% to ₹660, with an improved revenue forecast carrying the promise of a more valuable business, in time. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Indegene at ₹735 per share, while the most bearish prices it at ₹500. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. It's clear from the latest estimates that Indegene's rate of growth is expected to accelerate meaningfully, with the forecast 22% annualised revenue growth to the end of 2027 noticeably faster than its historical growth of 17% p.a. over the past three years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to grow their revenue at 17% per year. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect Indegene to grow faster than the wider industry.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. Pleasantly, they also upgraded their revenue estimates, and their forecasts suggest the business is expected to grow faster than the wider industry. There was also a nice increase in the price target, with the analysts clearly feeling that the intrinsic value of the business is improving.
Following on from that line of thought, we think that the long-term prospects of the business are much more relevant than next year's earnings. We have estimates - from multiple Indegene analysts - going out to 2029, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 1 warning sign for Indegene you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.